DEXCOM, INC.

Dexcom, Inc. is a leader in continuous glucose monitoring (CGM) systems and glucose biosensing technology, founded in 1999 and headquartered in San Diego, California. The company develops real-time glucose sensing devices that transmit glucose readings directly to smartphones and receivers, enabling people with diabetes to monitor their blood glucose levels continuously and make informed treatment decisions. Dexcom's primary product line includes the Dexcom G7 CGM System and the Dexcom G7 15 Day sensor, designed for adults 18+ with all types of diabetes. The G7 offers best-in-class accuracy and an extended 15-day wear period, with approximately 74% of sensors lasting the full duration. The company also offers Stelo Glucose Biosensor, an over-the-counter (OTC) integrated CGM intended for people 18+ not on insulin, including those with prediabetes or seeking general wellness optimization. Stelo requires no prescription, no fingersticks, and delivers personal glucose insights to users' phones. Dexcom's ecosystem includes connectivity with multiple smart devices and partner integrations to reduce the burden of diabetes management. The company serves patients across multiple insurance channels including commercial, Medicare Advantage, Medicare, Medicaid, VA Health Care, and Kaiser, as well as uninsured/cash-pay patients. Dexcom maintains FDA 510(k) clearance and regulatory compliance for its medical devices and supports healthcare providers through a dedicated provider portal. Manufacturing and distribution capabilities include pharmacy and medical supplier channels.